-
Home
-
Advocacy
- Advocacy Toolkit
Advocacy Toolkit
Overview |
|
 |
This toolkit provides a one-stop resource for patients and patient groups interested in plasma protein therapies. Access the Patient Notification System, PPTA Fact Sheets, Issue Briefs, Stakeholder Reports, Health Policy updates, and connect with other patient groups and consumer organizations. The toolkit includes a wealth of information resources. An easy to follow format facilitates quick access to PPTA's efforts in both Europe and the U.S. Learn more about the Association's advocacy efforts to ensure patient access to therapies. You may use this information to frame your own advocacy efforts, educate your constituents, and strengthen your communications. If you have any questions or require additional information, a quick guide to PPTA staff is provided. |
Resources |
|
Downloadable ResourcesPlasma Protein Therapies - Uniquely Saving Lives (Available for Europe and North America) Download for Europe
|
|
Advocacy
PPTA News
-
PPTA Highlights Importance of Patient Access to Plasma Protein Therapies +
On July 16, the Plasma Protein Therapeutics Association (PPTA) submitted comments following the Trump administration’s “American Patients First” drug policy blueprint. In any discussions impacting the ability of individuals living with rare, chronic, and life-threatening diseases, PPTA remains steadfast to its mission to promote the availability of and access to safe and effective plasma protein therapies for all patients in the world.
Read More -
Statement on Romanian Competition Council +
To our big surprise representatives from the Romanian Competition Authority arrived at our offices in Brussels on June 26 and were joined by Belgian police and the Belgian Competition Authority. The investigators were interested to know whether there was a coordinated effort to restrict supply of immunoglobulin therapies to the Romanian market for the purposes of pressuring the government to exempt these therapies from the “claw back” tax. PPTA cooperated fully with the investigators.
Read More -
Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA) +
The pharmaceutical industry represented by AESGP1, EFPIA2, EUCOPE3, EuropaBio4, Medicines for Europe and PPTA5 – henceforth referred to as ‘the pharmaceutical industry’ – generally welcomes the European Commission (EC)’s Proposal for a Regulation on HTA6. We understand the scope of the joint clinical assessments foreseen in the proposal is limited to medicinal products subject to the centralised marketing authorisation, and exempting generic, biosimilar and non-prescription medicines7.
Read More
- 1
- 2
- 3
The Source, the international magazine of the plasma protein therapeutics industry, is published quarterly.
Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.